Welcome to our dedicated page for CIBUS news (Ticker: CBUS), a resource for investors and traders seeking the latest updates and insights on CIBUS stock.
Cibus, Inc. (Nasdaq: CBUS) is an agricultural technology company that develops and licenses gene-edited plant traits to seed companies, with a focus on productivity traits for major row crops. The CBUS news page on Stock Titan aggregates company announcements, business updates, regulatory milestones, and collaboration news directly relevant to Cibus’ trait development and commercialization plans.
In its news releases, Cibus highlights progress in rice herbicide-tolerance traits HT1 and HT3, including material transfer agreements and a non-binding letter of intent with organizations and companies in Latin America to introduce these traits into elite rice germplasm and to prepare for commercialization in key rice-producing markets. The company also reports on collaborations aimed at bringing its gene editing technologies to India’s rice seed industry through strategic advisory partnerships.
News coverage for CBUS also includes updates on canola trait programs, such as positive field trial results for its HT2 herbicide-tolerance trait in North America and field trials for pod shatter reduction and disease resistance traits in winter oilseed rape. Additional items describe Cibus’ sustainable ingredients program, where the company has completed pre-commercial pilot runs for certain biofragrance products and received initial payments associated with commercialization efforts.
Investors and observers can use the CBUS news feed to follow Cibus’ participation in regulatory developments around gene editing in regions such as the European Union, the United Kingdom, North America and Ecuador, as well as corporate governance changes, board appointments, workforce adjustments and strategic focus updates. Regular visits to this page provide a consolidated view of how Cibus’ trait pipeline, partnerships and regulatory environment are evolving over time.
Cibus (Nasdaq: CBUS) will report fourth quarter 2025 financial results on Tuesday, March 17, 2026 after the market close. Management will host a conference call and audio webcast at 4:30 p.m. ET to discuss results and company updates.
Dial-in numbers, conference ID, replay details, and a live webcast with slides will be available on the company's Investor Events page; an archived webcast will remain available for 90 days.
Cibus (Nasdaq: CBUS) is partnering with the John Innes Centre and other academic and industry collaborators on the UK Government–funded LLS-ERASED precision breeding project to develop durable resistance to Light Leaf Spot in oilseed rape using its Rapid Trait Development System™.
The initiative targets a disease that caused an estimated £300m in grower losses in 2022 and is supported by Defra’s Farming Innovation Programme and at least £21.5m in new funding across 15 projects, aiming to bring precision-bred varieties to UK growers.
Cibus (Nasdaq: CBUS) priced an underwritten public offering of 13,333,333 shares of Class A common stock at $1.50 per share, generating gross proceeds of approximately $20.0 million (or $23.0 million if the underwriter fully exercises a 30-day option).
Board members agreed to purchase 1,000,000 shares. The offering is expected to close on January 30, 2026, with net proceeds intended for working capital and to fund development of weed management traits in rice.
Cibus (Nasdaq: CBUS) announced a proposed underwritten public offering of its Class A common stock on Jan 28, 2026. BTIG is sole underwriter and may receive a 30-day option to buy up to 15% additional shares. Proceeds are intended for working capital, development of rice weed-management traits, and professional expenses. Certain board members indicated non-binding interest to purchase shares. The offering is made under an effective Form S-3 shelf registration and is subject to market conditions; final size, price, and timing remain uncertain.
Cibus (Nasdaq: CBUS) and Interoc executed a non-binding Letter of Intent to create a framework for commercializing co-developed herbicide-tolerant (HT) rice traits, targeting initial market entry in Ecuador and Colombia in 2027 and phased expansion into Peru, Central America and the Caribbean.
The LOI builds on a 2024 material transfer agreement under which Cibus integrated HT traits into Interoc germplasm; Cibus reports multi-location U.S. field trials for two traits, HT1 and HT3. The partners intend to negotiate a definitive licensing and marketing agreement to drive adoption and generate revenue for rice growers across the region.
Cibus (Nasdaq: CBUS) welcomed the positive conclusion of trilogue negotiations on the European Union's New Genomic Techniques (NGTs) legislation on Dec 11, 2025. The agreed text creates a regulatory framework for gene-edited plants and will move to formal endorsement by the European Parliament and Council.
The company noted the outcome aligns with the European Commission's original proposal on development, growing, intellectual property and seed access, follows the UK’s PBO rules effective Nov 13, 2025, and highlighted completed UK field trials for its pod shatter reduction trait in winter oilseed rape.
Cibus (Nasdaq: CBUS) reported third-quarter 2025 results and a year-to-date update on Nov 13, 2025. Key commercial progress includes seven Rice customer agreements representing an estimated 5–7 million addressable acres and >$200 million potential annual royalty opportunity. Company plans initial LATAM Rice launches in 2027 with Q4 2025 delivery of HT traits and field trials by year-end. Regulatory wins include USDA-APHIS “not regulated” for HT2 canola and Ecuador equivalence for HT1/HT3 Rice. Completed pre-commercial pilot for Sustainable Ingredients and received an initial payment in Q4 2025. Financials: cash $23.9M at Sept 30, 2025; Q3 R&D $10.8M, SG&A $5.3M; Q3 net loss $24.3M (EPS -$0.44). Targeting $30M annual net cash usage in 2026 and consolidated Oberlin into San Diego.
Cibus (Nasdaq: CBUS) announced on November 11, 2025 the election of Craig Wichner to its Board of Directors. Mr. Wichner will also serve on the Board’s Strategy Committee as Cibus prepares for anticipated commercial scaling of its gene-edited trait platform.
Wichner is founder and managing partner of Farmland LP, which manages more than $350 million in assets and over 19,000 acres, and brings experience in regenerative and organic farming, technology, real estate investment, and agribusiness development.
Cibus (Nasdaq: CBUS) will report third quarter 2025 financial results on Thursday, November 13, 2025 after the market close. Management will host a conference call and audio webcast at 4:30 p.m. ET to discuss results and company updates.
Dial-in participant numbers are +1-800-274-8461 (U.S.) and +1-203-518-9814 (International); the conference ID is “CIBUS” or 24287. A live webcast with accompanying slides will be available at investor.cibus.com/events. A replay will be available through Thursday, November 27, 2025, and the archived webcast will remain on the company website for 90 days after the event.
Cibus (Nasdaq: CBUS) announced a collaboration with AgVayā on October 16, 2025 to accelerate introduction of Cibus’ gene-editing technologies into India’s rice seed industry.
The agreement covers market strategy, stakeholder partnerships, and R&D and commercial collaborations aimed at developing resilient, high-yield rice varieties and advanced herbicide and sustainability traits. Cibus said the work could shorten breeding timelines in India by more than a decade, improve access to modern seed technologies, and help reduce pesticide dependence.